Alcon Stock

Alcon EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Alcon (ALC.SW) as of Jul 20, 2026 is 26.82. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 28.02 — a change of -4.31% (lower).

EV/EBIT

26.82

YoY

-4.31%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Alcon is 2026 26.82 . EV/EBIT (Enterprise Value to EBIT) of Alcon was 2025 28.02 . It decreases by -4.31% lower compared to the previous year.

The Alcon EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
122.10 base
Jan 1, 2020
-417.19 base
Jan 1, 2021
46.87 base
Jan 1, 2022
26.57 base
Jan 1, 2023
32.79 base
Jan 1, 2024
31.27 base
Jan 1, 2025
27.65 base
Jan 1, 2026 (e)
14.89 base
YEARPRICE-TO-EBIT
2026 est 14.89
2025 27.65
2024 31.27
2023 32.79
2022 26.57
2021 46.87
2020 -417.19
2019 122.10
2018 -
2017 -
2016 -
Access this data via the Eulerpool API
Get Free API Key

Alcon Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Alcon's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Alcon's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Alcon's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Alcon grows earnings faster than its peers.

Alcon Stock analysis

What does Alcon do? Alcon AG is a leading company in ophthalmology with more than 70 years of experience in this industry. The company was founded in 1945 by Robert Alexander and William Conner and has its headquarters in Geneva, Switzerland. Alcon AG has been part of the Novartis Group since 2019 and is a leader in the production of ophthalmic products. The business model of Alcon AG is based on the manufacturing and sale of ophthalmic products. The company offers medical products such as contact lenses, surgical instruments, eye drops, and intraocular lenses. Alcon AG specializes in the development of products that can be used for various eye diseases. The company provides a wide range of products that can be used by ophthalmologists and opticians. The various divisions of Alcon AG include eye care products, surgical products, and diagnostic products. Eye care products, such as contact lenses, offer consumers a safe and easy way to correct their vision. Surgical products include a wide range of instruments used in eye surgeries. Diagnostic products help identify eye diseases and support treatment. Alcon AG specializes in the development of products for the treatment of eye diseases. These include conditions such as cataracts, glaucoma, and age-related macular degeneration. The company offers various products that can be used for these conditions, such as eye drops to reduce elevated eye pressure in glaucoma. It has also developed a wide range of products for refractive correction, allowing people to improve their vision. Alcon AG works closely with leading ophthalmologists and opticians to optimize its product development. This close collaboration ensures that Alcon AG's products meet the needs of patients and provide them with high safety and effectiveness. With its innovative products and technologies, Alcon AG aims to improve the quality of life for patients and provide them with optimal care and treatment. Overall, Alcon AG is a leading company in ophthalmology, offering its customers a wide range of innovative and high-quality products. From diagnosis to care to surgical interventions, Alcon AG's product range covers all areas of ophthalmology. The company is known for its research and development and is constantly working towards advancing ophthalmology. Through its continuous innovation and customer orientation, Alcon AG has established a strong position in the healthcare industry and will continue to introduce new products and technologies in the future. Alcon is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Alcon stock

EV/EBIT (Enterprise Value to EBIT) of Alcon is 26.82 in 2026.

Access this data via the Eulerpool API
Get Free API Key

Valuation — Alcon

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueEV/EBITForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Alcon